HARVARD BIOSCIENCE INC — Director's Dealing 2018

Aug 9, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HARVARD BIOSCIENCE INC (HBIO)
CIK: 0001123494
Period of Report: 2018-08-07

Reporting Person: Duchemin Jeffrey (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-08-07	Common Stock	M	100000	$4.31	Acquired	890742	Direct
2018-08-07	Common Stock	S	100000	$6.07	Disposed	790742	Direct
2018-08-08	Common Stock	M	5500	$4.31	Acquired	796242	Direct
2018-08-08	Common Stock	S	5500	$6.35	Disposed	790742	Direct
2018-08-09	Common Stock	M	44500	$4.31	Acquired	835242	Direct
2018-08-09	Common Stock	S	44500	$6.41	Disposed	790742	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-08-07	Stock option (right to buy)	$4.31	M	100000	Disposed	2023-11-18	Common Stock, par value $0.01 per share (500000)	Direct
2018-08-08	Stock option (right to buy)	$4.31	M	5500	Disposed	2013-11-18	Common Stock, par value $0.01 per share (400000)	Direct
2018-08-09	Stock option (right to buy)	$4.31	M	44500	Disposed	2023-11-18	Common Stock, par value $0.01 per share (394500)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: Includes (a) a deferred stock award of 94,444 restricted stock units with performance based vesting conditions, which shall vest in three equal installments on May 24, 2019, May 24, 2020 and May 24, 2021, contingent upon achievement of a performance condition tied to relative total shareholder return; (b) a deferred stock award of 94,444 restricted stock units which shall vest in four equal installments on January 1, 2019, 2020, 2021 and 2022; (c) a deferred stock award of 268,206 restricted stock units which shall vest in three equal installments on January 1, 2019, 2020 and 2021; (d) a deferred stock award of 145,833 restricted stock units which shall vest in two equal installments on January 1, 2019 and 2020; (e) a deferred stock award of 17,225 restricted stock units which shall vest in full on January 1, 2019; (continued in footnote 3 below)

F3: (continuation of footnote 3 above) (f) a deferred stock award of 71,748 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (g) 198,842 shares of common stock held by the Reporting Person.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.15 to $6.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4).

F5: Includes the awards referenced in clauses (a) through (f) of footnotes (2) and (3) above plus 98,842 shares of common stock held by the Reporting Person.

F6: Includes the awards referenced in clauses (a) through (f) of footnotes (2) and (3) above plus 104,342 shares of common stock held by the Reporting Person.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.35 to $6.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7).

F8: Includes the awards referenced in clauses (a) through (f) of footnotes (2) and (3) above plus 143,342 shares of common stock held by the Reporting Person.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.35 to $6.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (9).